Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX) from its SEC filings: 2025 revenue $1.5 million (-78% vs the year before), net margin -16748%, free cash flow -$213.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Revenue (2025) | $1.5 million |
| Revenue growth | -78% |
| Net income | -$258.8 million |
| Net margin | -16748.0% |
| Free cash flow | -$213.7 million |
| Diluted EPS | $-3.90 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -97% |
| Cash | $47.5 million |
| Share count, 1 year | +18% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.